{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:35:40Z","timestamp":1794713740096,"version":"4.9.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018713","name":"Center for Innovative Medicine","doi-asserted-by":"publisher","award":["FoUI-1002840"],"award-info":[{"award-number":["FoUI-1002840"]}],"id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Alzheimer\u2019s Foundation","award":["AF-1032116"],"award-info":[{"award-number":["AF-1032116"]}]},{"DOI":"10.13039\/100007435","name":"\u00c5ke Wiberg Foundation","doi-asserted-by":"publisher","award":["M24-0221"],"award-info":[{"award-number":["M24-0221"]}],"id":[{"id":"10.13039\/100007435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-01428"],"award-info":[{"award-number":["2022-01428"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-01425"],"award-info":[{"award-number":["2022-01425"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024-03599"],"award-info":[{"award-number":["2024-03599"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Petrus and Augusta Hedlund Foundation","award":["M-2024-2526"],"award-info":[{"award-number":["M-2024-2526"]}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvall Foundation","doi-asserted-by":"publisher","award":["2024-1370"],"award-info":[{"award-number":["2024-1370"]}],"id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Kidney Foundation"},{"name":"Karolinska Institutet internal funds"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009745","name":"Emil and Wera Cornell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009745","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Dementia Foundation"},{"name":"Stockholm County Council and Karolinska Institutet"},{"name":"New Innovative Roads Call"},{"name":"Leif Lundblad"},{"name":"Loo and Hans Osterman Foundation"},{"name":"Gun and Bertil Stohne Foundation"},{"name":"Swedish Dementia Foundation"},{"name":"Tore Nilson Foundation"},{"name":"Gamla Tj\u00e4narinnor Foundation"},{"name":"Lindh\u00e9s Advokatbyr\u00e5 Foundation"},{"DOI":"10.13039\/100016413","name":"Mats Paulsson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"publisher","award":["FO2024-0339"],"award-info":[{"award-number":["FO2024-0339"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PREDEM","award":["2021-02680"],"award-info":[{"award-number":["2021-02680"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Use of non-vitamin K oral anticoagulants (NOACs) is associated with reduced dementia risk in patients with atrial fibrillation (AF), but their impact on cognitive function and clinical outcomes in AF patients with Alzheimer\u2019s disease (AD) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on the Swedish Registry for Cognitive\/Dementia Disorders, individuals with incident AD during May 2007\u2013December 2020 and pre-existing AF were identified. Anticoagulant use at baseline was categorized as non-use, warfarin, or NOACs. Inverse probability of treatment weighting was employed to balance covariates. Mixed-effects models were used to assess the association between anticoagulant use and cognitive decline measured by the Mini-Mental State Examination (MMSE). Cox proportional hazards models were used to examine risks of all-cause mortality, ischaemic stroke\/systemic embolism, major bleeding, and fracture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 7308 eligible individuals (3341 non-users, 2277 warfarin users, and 1690 NOAC users), NOAC users exhibited significantly slower cognitive decline compared to non-users (difference in MMSE scores \u03b2 = 0.23 points\/year, 95% confidence interval [CI] 0.11\u20130.36) and warfarin users (\u03b2 = 0.21 points\/year, 95% CI 0.10\u20130.33). Compared to non-use of anticoagulants, NOAC use was associated with significantly lower rates of mortality (hazard ratio [HR] 0.81; 95% CI 0.72\u20130.91), ischaemic stroke\/systemic embolism (HR 0.66; 95% CI 0.53\u20130.82), and fracture (HR 0.79; 95% CI 0.64\u20130.97), without an increased rate of major bleeding (HR 1.05; 95% CI 0.84\u20131.32); in contrast, warfarin use was associated with significantly lower rates of mortality (HR 0.88; 95% CI 0.80\u20130.97) and ischaemic stroke\/systemic embolism (HR 0.85; 95% CI 0.72\u20131.00), but a higher rate of major bleeding (HR 1.31; 95% CI 1.09\u20131.56). Compared to warfarin, NOAC use was associated with lower rates of ischaemic stroke\/systemic embolism (HR 0.78; 95% CI 0.62\u20130.98) and major bleeding (HR 0.80; 95% CI 0.64\u20131.01), and non-significant reductions in mortality and fracture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with AF and AD, NOAC use was associated with modestly slower cognitive decline and more favourable effectiveness and safety profiles, compared to warfarin or no anticoagulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag584","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:50:15Z","timestamp":1783684215000},"source":"Crossref","is-referenced-by-count":3,"title":["Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer\u2019s disease: a Swedish nationwide study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3501-1351","authenticated-orcid":false,"given":"Nanbo","family":"Zhu","sequence":"first","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet , 171 77 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-3431","authenticated-orcid":false,"given":"Hong","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet , 171 77 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1537-6129","authenticated-orcid":false,"given":"Sara","family":"Garcia-Ptacek","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet , 171 77 Stockholm ,","place":["Sweden"]},{"name":"Theme Inflammation and Aging, Karolinska University Hospital , 141 52 Huddinge ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6381-5344","authenticated-orcid":false,"given":"Sumonto","family":"Mitra","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet , 171 77 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2498-4000","authenticated-orcid":false,"given":"Maria","family":"Eriksdotter","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet , 171 77 Stockholm ,","place":["Sweden"]},{"name":"Theme Inflammation and Aging, Karolinska University Hospital , 141 52 Huddinge ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"2026081207011722400_ehag584-B1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jacc.2018.10.077","article-title":"Atrial fibrillation and cognitive function: JACC review topic of the week","volume":"73","author":"Diener","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026081207011722400_ehag584-B2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.121.055018","article-title":"Atrial fibrillation and dementia: a report from the AF-SCREEN international collaboration","volume":"145","author":"Rivard","year":"2022","journal-title":"Circulation"},{"key":"2026081207011722400_ehag584-B3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3233\/JAD-170575","article-title":"Treatment of atrial fibrillation in patients with dementia: a cohort study from the Swedish dementia registry","volume":"61","author":"Subic","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2026081207011722400_ehag584-B4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41569-018-0075-z","article-title":"Cognitive dysfunction in atrial fibrillation","volume":"15","author":"Madhavan","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026081207011722400_ehag584-B5","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026081207011722400_ehag584-B6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bph.16032","article-title":"Oral anticoagulants: a plausible new treatment for Alzheimer's disease?","volume":"181","author":"Toribio-Fernandez","year":"2024","journal-title":"Br J Pharmacol"},{"key":"2026081207011722400_ehag584-B7","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afae009","article-title":"Effects of rhythm-control and rate-control strategies on cognitive function and dementia in atrial fibrillation: a systematic review and meta-analysis","volume":"53","author":"Guo","year":"2024","journal-title":"Age Ageing"},{"key":"2026081207011722400_ehag584-B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.10.025","article-title":"Oral anticoagulants and risk of dementia: a systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"96","author":"Mongkhon","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"2026081207011722400_ehag584-B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/FJC.0000000000000925","article-title":"Association of risk of dementia with direct oral anticoagulants versus warfarin use in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis","volume":"77","author":"Lee","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026081207011722400_ehag584-B10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacasi.2023.07.012","article-title":"Dementia risk of direct oral anticoagulants versus warfarin for atrial fibrillation: systematic review and meta-analysis","volume":"3","author":"Fong","year":"2023","journal-title":"JACC Asia"},{"key":"2026081207011722400_ehag584-B11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12916-022-02563-2","article-title":"Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial","volume":"20","author":"Caramelli","year":"2022","journal-title":"BMC Med"},{"key":"2026081207011722400_ehag584-B12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/joa3.12781","article-title":"Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation [CAF] trial)","volume":"38","author":"Bunch","year":"2022","journal-title":"J Arrhythm"},{"key":"2026081207011722400_ehag584-B13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41591-025-04101-y","article-title":"Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial","volume":"32","author":"Rivard","year":"2026","journal-title":"Nat Med"},{"key":"2026081207011722400_ehag584-B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4086","article-title":"Comparative effectiveness and safety of oral anticoagulants by dementia Status in older patients with atrial fibrillation","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026081207011722400_ehag584-B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2025.102528","article-title":"Alzheimer's disease and vascular biology\u2014a focus on the procoagulant state","volume":"95","author":"Casquero-Veiga","year":"2025","journal-title":"Curr Opin Cell Biol"},{"key":"2026081207011722400_ehag584-B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2022.111725","article-title":"\u03b2-Amyloid promotes platelet activation and activated platelets act as bridge between risk factors and Alzheimer's disease","volume":"207","author":"Li","year":"2022","journal-title":"Mech Ageing Dev"},{"key":"2026081207011722400_ehag584-B17","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1073\/pnas.1423764112","article-title":"Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma","volume":"112","author":"Zamolodchikov","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026081207011722400_ehag584-B18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.neuron.2010.05.014","article-title":"Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease","volume":"66","author":"Cortes-Canteli","year":"2010","journal-title":"Neuron"},{"key":"2026081207011722400_ehag584-B19","doi-asserted-by":"publisher","first-page":"21812","DOI":"10.1073\/pnas.1010373107","article-title":"Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization","volume":"107","author":"Ahn","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026081207011722400_ehag584-B20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1172\/JCI97509","article-title":"Blood will out: vascular contributions to Alzheimer's disease","volume":"128","author":"Strickland","year":"2018","journal-title":"J Clin Invest"},{"key":"2026081207011722400_ehag584-B21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1084\/jem.20131751","article-title":"A novel A\u03b2-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice","volume":"211","author":"Ahn","year":"2014","journal-title":"J Exp Med"},{"key":"2026081207011722400_ehag584-B22","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2016-11-753202","article-title":"Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice","volume":"129","author":"Chen","year":"2017","journal-title":"Blood"},{"key":"2026081207011722400_ehag584-B23","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.jacc.2019.07.081","article-title":"Long-term dabigatran treatment delays Alzheimer's disease pathogenesis in the TgCRND8 mouse model","volume":"74","author":"Cortes-Canteli","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026081207011722400_ehag584-B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116538","article-title":"SveDem, the Swedish Dementia Registry\u2014a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice","volume":"10","author":"Religa","year":"2015","journal-title":"PLoS One"},{"key":"2026081207011722400_ehag584-B25","author":"Svenska registret f\u00f6r kognitiva sjukdomar\/demenssjukdomar"},{"key":"2026081207011722400_ehag584-B26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026081207011722400_ehag584-B27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"2026081207011722400_ehag584-B28","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026081207011722400_ehag584-B29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10654-025-01226-9","article-title":"The healthcare system in Sweden","volume":"40","author":"Ludvigsson","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"2026081207011722400_ehag584-B30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026081207011722400_ehag584-B31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10654-025-01221-0","article-title":"Diagnostic accuracy in the Swedish national patient register: a review including diagnoses in the outpatient register","volume":"40","author":"Everhov","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"2026081207011722400_ehag584-B32","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1160\/TH16-05-0400","article-title":"Usefulness of Health Registers for detection of bleeding events in outcome studies","volume":"116","author":"Friberg","year":"2016","journal-title":"Thromb Haemost"},{"key":"2026081207011722400_ehag584-B33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/aje\/kwaf050","article-title":"Inverse probability weighting for categorical exposures","volume":"195","author":"Naimi","year":"2026","journal-title":"Am J Epidemiol"},{"key":"2026081207011722400_ehag584-B34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/alz.12050","article-title":"Controlling for selective dropout in longitudinal dementia data: application to the SveDem registry","volume":"16","author":"Handels","year":"2020","journal-title":"Alzheimers Dement"},{"key":"2026081207011722400_ehag584-B35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/aje\/kwab235","article-title":"Implementation of an alternative method for assessing competing risks: restricted mean time lost","volume":"191","author":"Wu","year":"2022","journal-title":"Am J Epidemiol"},{"key":"2026081207011722400_ehag584-B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000365637","article-title":"Normalized Mini-Mental State Examination for assessing cognitive change in population-based brain aging studies","volume":"43","author":"Philipps","year":"2014","journal-title":"Neuroepidemiology"},{"key":"2026081207011722400_ehag584-B37","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70163","article-title":"Extension and external validation of mapping between the Mini-mental state examination and the clinical dementia rating scale in patients with Alzheimer's disease","volume":"21","author":"Brogaard","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2026081207011722400_ehag584-B38","doi-asserted-by":"publisher","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","article-title":"Long-term effects of cholinesterase inhibitors on cognitive decline and mortality","volume":"96","author":"Xu","year":"2021","journal-title":"Neurology"},{"key":"2026081207011722400_ehag584-B39","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14321","article-title":"Long-term cognitive function changes with non-vitamin K oral anticoagulants in older patients with atrial fibrillation. A multicenter cohort study","volume":"55","author":"Armentaro","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"2026081207011722400_ehag584-B40","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00258","article-title":"Non-vitamin K antagonist oral anticoagulants and cognitive impairment in atrial fibrillation: insights from the meta-analysis of over 90,000 patients of randomized controlled trials and real-world studies","volume":"10","author":"Zhang","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"2026081207011722400_ehag584-B41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3233\/JAD-200610","article-title":"Anticoagulants for treatment of Alzheimer's disease","volume":"77","author":"Grossmann","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"2026081207011722400_ehag584-B42","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"key":"2026081207011722400_ehag584-B43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrn.2018.13","article-title":"Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics","volume":"19","author":"Petersen","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"2026081207011722400_ehag584-B44","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1182\/blood-2011-11-389668","article-title":"A\u03b2 delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin","volume":"119","author":"Zamolodchikov","year":"2012","journal-title":"Blood"},{"key":"2026081207011722400_ehag584-B45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/NRR.NRR-D-23-02093","article-title":"Fibrinogen's potential role in connecting cerebrovascular abnormalities with glymphatic dysfunction in Alzheimer's disease","volume":"20","author":"Singh","year":"2025","journal-title":"Neural Regen Res"},{"key":"2026081207011722400_ehag584-B46","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1265331","article-title":"Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026081207011722400_ehag584-B47","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2026081207011722400_ehag584-B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2024.04.009","article-title":"Oral anticoagulant therapy in older adults","volume":"238","author":"Stuby","year":"2024","journal-title":"Thromb Res"},{"key":"2026081207011722400_ehag584-B49","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1161\/CIRCULATIONAHA.123.066279","article-title":"Efficacy and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin across the Spectrum of body mass Index and body weight: an individual patient data meta-analysis of 4 randomized clinical trials of patients with atrial fibrillation","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2026081207011722400_ehag584-B50","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2026081207011722400_ehag584-B51","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/eurheartj\/ehz952","article-title":"Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study","volume":"41","author":"Huang","year":"2020","journal-title":"Eur Heart J"},{"key":"2026081207011722400_ehag584-B52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/jamainternmed.2019.5679","article-title":"Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation","volume":"180","author":"Lutsey","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026081207011722400_ehag584-B53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1190762","article-title":"Alzheimer's disease and its associated risk of bone fractures: a narrative review","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026081207011722400_ehag584-B54","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2069176","article-title":"Vitamin K and bone health: a review on the effects of vitamin K deficiency and supplementation and the effect of non-vitamin k antagonist oral anticoagulants on different bone parameters","volume":"2019","author":"Rodriguez-Olleros Rodriguez","year":"2019","journal-title":"J Osteoporos"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag584\/70607427\/ehag584.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag584\/70607427\/ehag584.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:03:35Z","timestamp":1786532615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag584\/8758725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":54,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag584","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"ehag584"}}